Daclizumab Completed Phase 2 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00071838Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
NCT01051349Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis